Insmed (INSM) Announces EC Grants Marketing Authorization for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Tr

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. META
5. SPY
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Insmed (INSM) Announces EC Grants Marketing Authorization for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Tr

European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Tre

October 28, 2020 7:37 AM EDT

BRIDGEWATER, N.J., Oct. 28, 2020 /PRNewswire/ Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the European Commission (EC) has granted marketing authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion ("ARIKAYCE") for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

"We are... More